John Woock - Axonics Chief Marketing Officer
| 0I3 Stock | EUR 63.50 0.00 0.00% |
Insider
John Woock is Chief Marketing Officer of Axonics since 2018.
| Age | 39 |
| Tenure | 6 years |
| Phone | 949 396 6322 |
| Web | https://www.axonics.com |
John Woock Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Woock against Axonics stock is an integral part of due diligence when investing in Axonics. John Woock insider activity provides valuable insight into whether Axonics is net buyers or sellers over its current business cycle. Note, Axonics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Axonics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Woock over six months ago Exercise or conversion by John Woock of 28000 shares of Axonics Modulation subject to Rule 16b-3 | ||
John Woock over a year ago Axonics Modulation exotic insider transaction detected | ||
John Woock over a year ago Sale by John Woock of 100 shares of Axonics Modulation |
Axonics Management Efficiency
The company has return on total asset (ROA) of (0.0624) % which means that it has lost $0.0624 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1453) %, meaning that it generated substantial loss on money invested by shareholders. Axonics' management efficiency ratios could be used to measure how well Axonics manages its routine affairs as well as how well it operates its assets and liabilities.Axonics has accumulated 10.01 M in total debt with debt to equity ratio (D/E) of 0.02, which may suggest the company is not taking enough advantage from borrowing. Axonics has a current ratio of 13.35, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Axonics until it has trouble settling it off, either with new capital or with free cash flow. So, Axonics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Axonics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Axonics to invest in growth at high rates of return. When we think about Axonics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 13 records | INSIDER Age | ||
| Yoshihito Kikyo | Meiko Electronics Co | 68 | |
| Shigeru Naya | Meiko Electronics Co | 48 | |
| Shena BA | Western Copper and | N/A | |
| Jonathan Clegg | Western Copper and | N/A | |
| Kenneth BSc | Western Copper and | N/A | |
| Masakuni Shinozaki | Meiko Electronics Co | 71 | |
| Junya Wada | Meiko Electronics Co | 62 | |
| Atsushi Sakate | Meiko Electronics Co | 50 | |
| Sandy Noyes | Western Copper and | N/A | |
| Yuichiro Naya | Meiko Electronics Co | 80 | |
| CGA CPA | Western Copper and | N/A | |
| Elena BE | Western Copper and | N/A | |
| Cameron PEng | Western Copper and | N/A | |
Management Performance
| Return On Equity | -0.15 | |||
| Return On Asset | -0.0624 |
Axonics Leadership Team
Elected by the shareholders, the Axonics' board of directors comprises two types of representatives: Axonics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Axonics. The board's role is to monitor Axonics' management team and ensure that shareholders' interests are well served. Axonics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Axonics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erik Amble, Independent Director | ||
| Jane Kiernan, Independent Director | ||
| MD MAS, Chief Officer | ||
| Raymond Cohen, Chief Executive Officer, Director | ||
| Karen Noblett, Chief Medical Officer | ||
| JD Esq, Gen VP | ||
| John Woock, Chief Marketing Officer | ||
| Neil Bhalodkar, VP Relations | ||
| Nancy Snyderman, Independent Director | ||
| Robert McNamara, Independent Director | ||
| Alfred Ford, Chief Commercial Officer | ||
| Michael Carrel, Independent Chairman of the Board | ||
| Dan Dearen, President, Chief Financial Officer | ||
| Danny Dearen, Pres CFO | ||
| Rinda Sama, Chief Operating Officer | ||
| Juliet Bakker, Independent Director | ||
| Aaron Pettit, G Officer | ||
| David Demski, Director | ||
| Prabodh Mathur, Chief Product Development Officer | ||
| Guangqiang Jiang, Chief Technology Officer |
Axonics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Axonics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.0624 | |||
| Profit Margin | (0.31) % | |||
| Operating Margin | (0.25) % | |||
| Current Valuation | 2.7 B | |||
| Shares Outstanding | 49.53 M | |||
| Shares Owned By Insiders | 0.80 % | |||
| Shares Owned By Institutions | 99.20 % | |||
| Price To Book | 5.99 X | |||
| Price To Sales | 11.31 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Axonics Stock
Axonics financial ratios help investors to determine whether Axonics Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Axonics with respect to the benefits of owning Axonics security.